NASDAQ:ONVOOrganovo Stock Price, Forecast & News

Organovo's stock was trading at $0.26 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ONVO shares have increased by 132.3% and is now trading at $0.6040. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organovo in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Organovo.

Organovo is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Organovo.

Organovo Holdings Inc (NASDAQ:ONVO) released its quarterly earnings results on Thursday, August, 8th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.05). The medical research company had revenue of $0.67 million for the quarter, compared to analyst estimates of $0.77 million. Organovo had a negative return on equity of 60.96% and a negative net margin of 798.68%. View Organovo's earnings history.

Media stories about ONVO stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Organovo earned a media sentiment score of -1.8 on InfoTrie's scale. They also assigned news articles about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Organovo.

Organovo saw a decline in short interest in June. As of June 30th, there was short interest totaling 1,320,000 shares, a decline of 16.5% from the June 15th total of 1,580,000 shares. Based on an average daily volume of 1,530,000 shares, the short-interest ratio is presently 0.9 days. Currently, 1.0% of the company's shares are sold short. View Organovo's Current Options Chain.

Some companies that are related to Organovo include PDL BioPharma (PDLI), Cellular Biomedicine Group (CBMG), Cabaletta Bio (CABA), ADMA Biologics (ADMA), Dyadic International (DYAI), CASI Pharmaceuticals (CASI), Gritstone Oncology (GRTS), Eiger Biopharmaceuticals (EIGR), Jounce Therapeutics (JNCE), Pluristem Therapeutics (PSTI), Fennec Pharmaceuticals (FENC), GENFIT S A/ADR (GNFT), Sutro Biopharma (STRO), Verona Pharma (TARA) and Axcella Health (AXLA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), Blackstone Group (BX), LADENBURG THALM/SH SH (LTS), Novavax (NVAX), Exelixis (EXEL), Anavex Life Sciences (AVXL), Micron Technology (MU) and Advanced Micro Devices (AMD).

Organovo trades on the NASDAQ under the ticker symbol "ONVO."

Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ONVO stock can currently be purchased for approximately $0.60.

Organovo has a market capitalization of $78.86 million and generates $2.20 million in revenue each year. Organovo employs 70 workers across the globe.

The official website for Organovo is www.organovo.com.

Organovo's mailing address is 440 STEVENS AVENUE SUITE 200, SOLANA BEACH CA, 92075. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected]